Conditions: Kawasaki Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 24
Healthy volunteers: no

Brief summary:
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Detailed description:
This study is an exploratory, pilot study to examine tolerance and pharmacokinetics of infliximab in infants and children with acute Kawasaki Disease.

Arms:
arm 1: Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg) arm 2: Remicade (5mg/kg) single dose

Interventions: intervention 1: Infliximab (Remicade) intervention 2: Intravenous immunoglobulin (IVIG)
Intervention descriptions: intervention 1: Remicade was 5 mg/kg IV (single dose) intervention 2: 2nd dose of IVIG (2g/kg)

Protocol document: